Skip to main content

Table 1 Demographic and clinical characteristics of all study subjects who underwent the first prostate biopsy

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

  Total No cancer Cancer P value
  N, 140  N, 77 (55%) N, 63 (45%)
Age, yr 69.0 (10.0) 67.0 (9.0) 72.0 (10.0) 0.001
tPSA, ng/mL 6.93 (6.05) 6.45 (3.8) 8.18 (15.3) 0.010
fPSA 1.03 (0.92) 0.92 (0.8) 1.07 (1.4) 0.160
%fPSA 14.55 (9.29) 17.13 (8.0) 11.16 (9.0) 0.003
p2PSA, pg/mL 19.18 (30.97) 15.54 (16.7) 31.06 (58.6) < 0.001
%p2PSA 2.02 (2.21) 1.57 (1.5) 2.83 (2.6) < 0.001
PHI 45.90 (82.72) 39.54 (38.0) 91.18 (147.9) < 0.001
Positive core number 5.0 (7.0)
Number (percentage)
GS 6% 15 (23.8%)
GS 7    18 (28.6%)
GS ≥ 8    30 (47.6%)
  1. Data are shown as median (interquartile range), or number (%)
  2. PSA, prostate-specific antigen; tPSA, total PSA; fPSA, free PSA; p2PSA, [2]proPSA, PHI, prostate health index; GS, Gleason score
  3. P value to be statiscally significant with bolditalics